title: Role of colesevelam in combination lipid-lowering therapy.
abstract: Hyperlipidemia is associated with an increased risk of cardiovascular events; reducing low-density lipoprotein cholesterol (LDL-C), the primary target for cholesterol-lowering therapy, lowers the risk for such events. Although bile acid sequestrants were the first class of drugs to show a mortality benefit related to LDL-C lowering, statins are now considered first-line pharmacological therapy for reducing LDL-C levels because of their potency and their remarkable record of successful outcomes studies. Nevertheless, a substantial proportion of patients do not achieve LDL-C goals with statin monotherapy. In addition, because of adverse effects (primarily myopathy), some patients may be unwilling to use or unable to tolerate statin therapy at all or may not tolerate a full therapeutic statin dose. Also, statins may increase risk of new-onset diabetes in patients at high risk for diabetes. Thus, there remains a need for other lipid-lowering drugs to be used in combination with or in place of statins. The purpose of this article is to review available data from the literature on the use of colesevelam, a second-generation bile acid sequestrant, in combination with other lipid-lowering agents. Colesevelam has been studied in combination with statins, niacin, fibrates, and ezetimibe (including some three-drug combinations). An additive reduction in LDL-C was seen with all combinations. Other observed effects of colesevelam in combination with other lipid-lowering drugs include reductions in apolipoprotein (apo) B (with statins, fibrates, ezetimibe, statin plus niacin, or statin plus ezetimibe) and high-sensitivity C-reactive protein (with statins), and increases in apo A-I (with statins, ezetimibe, or statins plus niacin). Triglyceride levels remained relatively unchanged when colesevelam was combined with statins, fibrates, ezetimibe, or statin plus ezetimibe, and decreased with the triple combination of colesevelam, statin, and niacin. Colesevelam offset the negative glycemic effects of statins and niacin in subjects with insulin resistance or impaired glucose tolerance. Colesevelam was generally well tolerated when added to other lipid-lowering therapies in clinical trials, with gastrointestinal effects such as constipation being the predominant adverse events. Since colesevelam is not absorbed and works primarily in the intestine, it has a low potential for systemic metabolic drug-drug interactions with other drugs. Colesevelam has been shown to not interact with the lipid-lowering drugs lovastatin and fenofibrate; where interaction may be anticipated, separating dosing times by 4 h reduces the impact of any interaction. Available data confirms that colesevelam has additive cholesterol-lowering effects when used in combination with other lipid-lowering therapies. Furthermore, in some patient populations, the additional glucose-lowering effect of colesevelam may be beneficial in offsetting hyperglycemic effects of other lipid-lowering drugs.
authors.affiliation: , Port St. Lucie, FL, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Jones
authors.forename: Oliseyenum M
authors.initials: OM
authors.lastname: Nwose
mesh_terms: D000499:Allylamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood; D000069472:Colesevelam Hydrochloride; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D000499:Allylamine; D000069472:Colesevelam Hydrochloride
references.citation: Curr Med Res Opin. 2006 Nov;22(11):2191-200
references.pmid: 17076980
references.citation: Metabolism. 2006 Dec;55(12):1697-703
references.pmid: 17142146
references.citation: Curr Med Res Opin. 2005 Sep;21(9):1403-12
references.pmid: 16197659
references.citation: J Intern Med. 2009 May;265(5):568-80
references.pmid: 19141093
references.citation: Am J Hypertens. 1993 Nov;6(11 Pt 2):375S-382S
references.pmid: 8297546
references.citation: Pharmacol Rep. 2012;64(2):377-85
references.pmid: 22661189
references.citation: J Clin Pharmacol. 2014 Jan;54(1):61-9
references.pmid: 24019110
references.citation: JAMA. 1984 Jan 20;251(3):351-64
references.pmid: 6361299
references.citation: Diabetes Care. 2013 May;36(5):1236-40
references.pmid: 23248196
references.citation: Circulation. 2002 Dec 17;106(25):3143-421
references.pmid: 12485966
references.citation: JAMA. 1972 Nov 6;222(6):676-81
references.pmid: 4562098
references.citation: Biol Pharm Bull. 1996 Sep;19(9):1231-3
references.pmid: 8889048
references.citation: Clin Ther. 2010 Apr;32(4):615-25
references.pmid: 20435231
references.citation: Am J Cardiol. 2006 Apr 15;97(8):1198-205
references.pmid: 16616026
references.citation: Diabetes Care. 2013 Jan;36 Suppl 1:S11-66
references.pmid: 23264422
references.citation: J Clin Lipidol. 2011 Nov-Dec;5(6):474-82
references.pmid: 22108151
references.citation: Calif Med. 1967 Apr;106(4):293-5
references.pmid: 4859983
references.citation: Lancet. 2009 Mar 14;373(9667):929-40
references.pmid: 19286092
references.citation: J Clin Pharmacol. 2010 May;50(5):554-65
references.pmid: 19789374
references.citation: Circulation. 2004 Jul 13;110(2):227-39
references.pmid: 15249516
references.citation: Am J Med. 2006 Aug;119(8):676-83
references.pmid: 16887414
references.citation: JAMA. 2011 Jun 22;305(24):2556-64
references.pmid: 21693744
references.citation: Atherosclerosis. 1970 May-Jun;11(3):531-7
references.pmid: 5433090
references.citation: Pharmacotherapy. 2010 Jun;30(6):541-53
references.pmid: 20500044
references.citation: Am J Cardiovasc Drugs. 2008;8(6):373-418
references.pmid: 19159124
references.citation: Diabetes Res Clin Pract. 2014 Jun;104(3):401-9
references.pmid: 24721587
references.citation: Arch Intern Med. 2000 Feb 28;160(4):459-67
references.pmid: 10695686
references.citation: J Clin Pharmacol. 1990 Jan;30(1):29-32
references.pmid: 2303577
references.citation: Clin Pharmacokinet. 2004;43(13):943-50
references.pmid: 15509187
references.citation: Metab Syndr Relat Disord. 2009 Jun;7(3):255-8
references.pmid: 19344229
references.citation: Diabetes Care. 2008 Aug;31(8):1479-84
references.pmid: 18458145
references.citation: N Engl J Med. 2011 Dec 15;365(24):2255-67
references.pmid: 22085343
references.citation: Curr Opin Rheumatol. 2010 Nov;22(6):644-50
references.pmid: 20827205
references.citation: Am J Med. 2001 Apr 1;110(5):352-60
references.pmid: 11286949
references.citation: Clin Cardiol. 2001 Jun;24(6):467-74
references.pmid: 11403509
references.citation: Lancet. 2012 Aug 11;380(9841):581-90
references.pmid: 22607822
references.citation: Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):530-40
references.pmid: 20577089
references.citation: J Am Coll Cardiol. 2013 Jan 15;61(2):148-52
references.pmid: 23219296
references.citation: Lancet. 2010 Feb 27;375(9716):735-42
references.pmid: 20167359
references.citation: Metab Syndr Relat Disord. 2013 Jun;11(3):152-6
references.pmid: 23170931
references.citation: JAMA Intern Med. 2013 Jul 22;173(14):1-10
references.pmid: 23877079
references.citation: Arch Intern Med. 2008 Jul 28;168(14):1531-40
references.pmid: 18663165
references.citation: Lancet. 1994 Nov 19;344(8934):1383-9
references.pmid: 7968073
references.citation: J Clin Lipidol. 2007 Dec;1(6):620-5
references.pmid: 21291704
references.citation: Fundam Clin Pharmacol. 2010 Feb;24(1):19-28
references.pmid: 19682080
references.citation: Br J Clin Pharmacol. 2013 Apr;75(4):1118-24
references.pmid: 22845189
references.citation: Lancet. 2010 Nov 13;376(9753):1658-69
references.pmid: 21067805
references.citation: Clin Ther. 2007 Feb;29(2):253-60
references.pmid: 17472818
references.citation: Arch Intern Med. 1988 Jan;148(1):36-69
references.pmid: 3422148
references.citation: J Clin Lipidol. 2013 Sep-Oct;7(5):423-32
references.pmid: 24079283
references.citation: Ann Pharmacother. 2002 Mar;36(3):392-7
references.pmid: 11895049
references.citation: Metabolism. 1964 Dec;13:1462-8
references.pmid: 14257087
references.citation: Eur J Clin Invest. 1986 Oct;16(5):391-6
references.pmid: 3100307
references.citation: Arch Intern Med. 2008 Oct 13;168(18):1975-83
references.pmid: 18852398
references.citation: N Engl J Med. 1981 Jan 29;304(5):251-8
references.pmid: 7003391
references.citation: Atherosclerosis. 2001 Oct;158(2):407-16
references.pmid: 11583720
references.citation: Cardiovasc Drugs Ther. 2000 Dec;14(6):681-90
references.pmid: 11300370
references.citation: BMJ Open. 2012 Sep 13;2(5):
references.pmid: 22983785
references.citation: JAMA. 1984 Jan 20;251(3):365-74
references.pmid: 6361300
references.citation: Eur Heart J. 2011 Jul;32(14):1769-818
references.pmid: 21712404
references.citation: N Engl J Med. 1995 Nov 16;333(20):1301-7
references.pmid: 7566020
references.citation: N Engl J Med. 2011 Jul 28;365(4):285-7
references.pmid: 21675881
references.citation: J Clin Pharmacol New Drugs. 1972 Jul;12(7):268-73
references.pmid: 4557535
references.citation: JAMA. 1965 Apr 26;192:289-93
references.pmid: 14271976
references.citation: Ann Intern Med. 2009 Nov 3;151(9):622-30
references.pmid: 19884623